Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Shares of drugmaker Eli Lilly LLY.N rise 12.7% to $828.67 premarket

Company says its small molecule oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial

Shares of Structure Therapeutics GPCR.O, which is also developing a small molecule oral weight loss drug, gain 17.7% before the bell

U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 6%

Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 5.1% and Amgen AMGN.O down 2.8%

Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD